Transarterial Chemoembolization Plus Lenvatinib and PD-1 Inhibitors for Hepatocellular Carcinoma with Main Trunk Portal Vein Tumor Thrombus: A Multicenter Retrospective Study

References

• Forner A, Reig M, Bruix J. Hepatocellular carcinoma. Lancet. 2018;391(10127):1301–1314. doi:10.1016/S0140-6736(18)30010-2
   PubMed Web of Science ®Google Scholar
• Cheng S, Chen M, Cai J, et al. Chinese Expert Consensus on multidisciplinary diagnosis and treatment of hepatocellular carcinoma with portal vein tumor thrombus (2018 Edition). Liver Cancer. 2020;9(1):28–40. doi:10.1159/000503685
   PubMed Web of Science ®Google Scholar
• Bruix J, Sherman M, Llovet JM, et al. Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL Conference. European Association for the Study of the Liver. J Hepatol. 2001;35(3):421–430. doi:10.1016/s0168-827(01)00130-1
   PubMed Web of Science ®Google Scholar
• Kokudo N, Takemura N, Hasegawa K, et al. Clinical practice guidelines for hepatocellular carcinoma: the Japan Society of Hepatology 2017 (4th JSH-HCC guidelines) 2019 update. Hepatol Res. 2019;49(10):1109–1113. doi:10.1111/hepr.13411
   PubMed Web of Science ®Google Scholar
• Xie DY, Ren ZG, Zhou J, Fan J, Gao Q. 2019 Chinese clinical guidelines for the management of hepatocellular carcinoma: updates and insights. Hepatobiliary Surg Nutr. 2020;9(4):452–463. doi:10.21037/hbsn-20-480
   PubMed Web of Science ®Google Scholar
• Xue TC, Xie XY, Zhang L, Yin X, Zhang BH, Ren ZG. Transarterial chemoembolization for hepatocellular carcinoma with portal vein tumor thrombus: a meta-analysis. BMC Gastroenterol. 2013;13(1):60. doi:10.1186/1471-230X-13-60
   PubMedGoogle Scholar
• Sun J, Shi J, Huang B, et al. The degree of hepatic arterial blood supply of portal vein tumor thrombus in patients with hepatocellular carcinoma and its impact on overall survival after transarterial chemoembolization. Oncotarget. 2017;8(45):79816–79824. doi:10.18632/oncotarget.19767
   PubMedGoogle Scholar
• Ajit Y, Sudarsan H, Saumya G, et al. Transarterial chemoembolization in unresectable hepatocellular carcinoma with portal vein thrombosis: a perspective on survival. Oman Med J. 2014;29(6):430–436. doi:10.5001/omj.2014.114
   PubMedGoogle Scholar
• Chung GE, Lee JH, Kim HY, et al. Transarterial chemoembolization can be safely performed in patients with hepatocellular carcinoma invading the main portal vein and may improve the overall survival. Radiology. 2011;258(2):627–634. doi:10.1148/radiol.10101058
   PubMed Web of Science ®Google Scholar
• Wu JY, Yin ZY, Bai YN, et al. Lenvatinib combined with anti-PD-1 antibodies plus transcatheter arterial chemoembolization for unresectable hepatocellular carcinoma: a multicenter retrospective study. J Hepatocell Carcinoma. 2021;8:1233–1240. doi:10.2147/JHC.S332420
   PubMed Web of Science ®Google Scholar
• Sandrasegaran K, Tahir B, Nutakki K, et al. Usefulness of conventional MRI sequences and diffusion-weighted imaging in differentiating malignant from benign portal vein thrombus in cirrhotic patients. AJR Am J Roentgenol. 2013;201(6):1211–1219. doi:10.2214/AJR.12.10171
   PubMed Web of Science ®Google Scholar
• Kudo M, Izumi N, Kubo S, et al. Report of the 20th nationwide follow-up survey of primary liver cancer in Japan. Hepatol Res. 2020;50(1):15–46. doi:10.1111/hepr.1343810
   PubMed Web of Science ®Google Scholar
• Mahringer-Kunz A, Steinle V, Duber C, et al. Extent of portal vein tumour thrombosis in patients with hepatocellular carcinoma: the more, the worse? Liver Int. 2019;39(2):324–331. doi:10.1111/liv.13988
   PubMed Web of Science ®Google Scholar
• Lencioni R, Llovet JM. Modified RECIST (mRECIST) assessment for hepatocellular carcinoma. Semin Liver Dis. 2010;30(1):52–60. doi:10.1055/s-0030-1247132
   PubMed Web of Science ®Google Scholar
• Cong WM, Bu H, Chen J, et al. Practice guidelines for the pathological diagnosis of primary liver cancer: 2015 update. World J Gastroenterol. 2016;22(42):9279–9287. doi:10.3748/wjg.v22.i42.9279
   PubMed Web of Science ®Google Scholar
• Qadan M, Kothary N, Sangro B, Palta M. The treatment of hepatocellular carcinoma with portal vein tumor thrombosis. Am Soc Clin Oncol Educ Book. 2020;40:1–8. doi:10.1200/EDBK_280811
   PubMedGoogle Scholar
• Kim HC, Chung JW, Lee W, Jae HJ, Park JH. Recognizing extrahepatic collateral vessels that supply hepatocellular carcinoma to avoid complications of transcatheter arterial chemoembolization. RadioGraphics. 2005;25(suppl 1):S25–S39. doi:10.1148/rg.25si055508
   PubMedGoogle Scholar
• Zhang W, Hu B, Han J, et al. Surgery after conversion therapy with PD-1 inhibitors plus tyrosine kinase inhibitors are effective and safe for advanced hepatocellular carcinoma: a pilot study of ten patients. Front Oncol. 2021;11:747950. doi:10.3389/fonc.2021.747950
   PubMed Web of Science ®Google Scholar
• Liu J, Li Z, Zhang W, et al. Comprehensive treatment of trans-arterial chemoembolization plus lenvatinib followed by camrelizumab for advanced hepatocellular carcinoma patients. Front Pharmacol. 2021;12:709060. doi:10.3389/fphar.2021.709060
   PubMed Web of Science ®Google Scholar
• Ju S, Zhou C, Yang C, et al. Apatinib plus camrelizumab with/without chemoembolization for hepatocellular carcinoma: a real-world experience of a single center. Front Oncol. 2021;11:835889. doi:10.3389/fonc.2021.835889
   PubMed Web of Science ®Google Scholar
• Teng Y, Ding X, Li W, Sun W, Chen J. A retrospective study on therapeutic efficacy of transarterial chemoembolization combined with immune checkpoint inhibitors plus lenvatinib in patients with unresectable hepatocellular carcinoma. Technol Cancer Res Treat. 2022;21:15330338221075174. doi:10.1177/15330338221075174
   Web of Science ®Google Scholar
• Cai M, Huang W, Huang J, et al. Transarterial chemoembolization combined with lenvatinib plus PD-1 inhibitor for advanced hepatocellular carcinoma: a retrospective cohort study. Front Immunol. 2022;13:848387. doi:10.3389/fimmu.2022.848387
   PubMed Web of Science ®Google Scholar
• Luo J, Guo RP, Lai ECH, et al. Transarterial chemoembolization for unresectable hepatocellular carcinoma with portal vein tumor thrombosis: a prospective comparative study. Ann Surg Oncol. 2011;18(2):413–420. doi:10.1245/s10434-010-1321-8
   PubMed Web of Science ®Google Scholar
• Niu ZJ, Ma YL, Kang P, et al. Transarterial chemoembolization compared with conservative treatment for advanced hepatocellular carcinoma with portal vein tumor thrombus: using a new classification. Med Oncol. 2012;29(4):2992–2997. doi:10.1007/s12032-011-0145-0
   PubMed Web of Science ®Google Scholar
• Nakazawa T, Hidaka H, Shibuya A, et al. Overall survival in response to sorafenib versus radiotherapy in unresectable hepatocellular carcinoma with major portal vein tumor thrombosis: propensity score analysis. BMC Gastroenterol. 2014;14(1):84. doi:10.1186/1471-230X-14-84
   PubMed Web of Science ®Google Scholar
• Mukozu T, Nagai H, Matsui D, et al. Adaptation of lenvatinib treatment in patients with hepatocellular carcinoma and portal vein tumor thrombosis. Cancer Chemother Pharmacol. 2022;89(1):11–20. doi:10.1007/s00280-021-04359-2
   PubMed Web of Science ®Google Scholar
• Zheng K, Zhu X, Fu S, et al. Sorafenib plus hepatic arterial infusion chemotherapy versus sorafenib for hepatocellular carcinoma with major portal vein tumor thrombosis: a randomized trial. Radiology. 2022;303(2):455–464. doi:10.1148/radiol.211545
   PubMed Web of Science ®Google Scholar
• Yuan G, Cheng X, Li Q, et al. Safety and efficacy of camrelizumab combined with apatinib for advanced hepatocellular carcinoma with portal vein tumor thrombus: a multicenter retrospective study. Onco Targets Ther. 2020;13:12683–12693. doi:10.2147/OTT.S286169
   PubMed Web of Science ®Google Scholar
• Reig M, Forner A, Rimola J, et al. BCLC strategy for prognosis prediction and treatment recommendation: the 2022 update. J Hepatol. 2022;76(3):681–693. doi:10.1016/j.jhep.2021.11.018
   PubMed Web of Science ®Google Scholar
• Kudo M, Kawamura Y, Hasegawa K, et al. Management of hepatocellular carcinoma in Japan: JSH consensus statements and recommendations 2021 update. Liver Cancer. 2021;10(3):181–223. doi:10.1159/000514174
   PubMed Web of Science ®Google Scholar
• Ho MC, Hasegawa K, Chen XP, et al. Surgery for intermediate and advanced hepatocellular carcinoma: a consensus report from the 5th Asia-Pacific Primary Liver Cancer Expert Meeting (APPLE 2014). Liver Cancer. 2016;5(4):245–256. doi:10.1159/000449336
   PubMed Web of Science ®Google Scholar
• Peng ZW, Guo RP, Zhang YJ, Lin XJ, Chen MS, Lau WY. Hepatic resection versus transcatheter arterial chemoembolization for the treatment of hepatocellular carcinoma with portal vein tumor thrombus. Cancer. 2012;118(19):4725–4736. doi:10.1002/cncr.26561
   PubMed Web of Science ®Google Scholar